CA Patent

CA3026889C — Improved synthesis of the radiolabeled prostate-specific membrane antigen (psma) inhibitor [18f]dcfpyl

Assigned to Johns Hopkins University · Expires 2024-10-01 · 2y expired

What this patent protects

Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.

USPTO Abstract

Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.

Drugs covered by this patent

Patent Metadata

Patent number: CA3026889C
Jurisdiction: CA
Classification: —
Expires: 2024-10-01
Drug substance claim: No
Drug product claim: No
Assignee: Johns Hopkins University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.